BRAF and melanoma: We also noted a substantial increase in cell surface expression of calreticulin (Fig. S2d) in human SK-MEL-28 melanoma cells, and especially in the IGR39 cell line that is known to be BRAF inhibitor tolerant and displays gene expression signatures linked to immunotherapy resistance [28].